Regulatory expertise Medis specializes in out-licensing generic pharmaceutical products and has a proven track record of securing regulatory approvals prior to patent expiries, with marketing authorizations in over 100 countries. This positions them as a strategic partner for pharma companies seeking fast regulatory routes and robust compliance.

Backed by Teva With full backing from Teva Pharmaceutical Industries, Medis leverages established development and manufacturing capabilities and in-house expertise. This offers potential buyers risk reduction, scalable supply, and access to a broader technical ecosystem.

Diverse portfolio A broad catalog of 200+ generic products, including growing oncology formulations and solid oral dosages, provides opportunities for co-licensing, portfolio expansion, and entry points into new therapeutic areas for partner pipelines.

Global reach Medis has supported marketing authorizations in over 100 countries, indicating strong international regulatory exposure and potential to accelerate global market access for partner products through established regulatory pathways.

Strategic relationships Longstanding customer relationships spanning over four decades suggest high-value collaboration opportunities, repeat business potential, and a favorable reference profile when engaging new pharmaceutical partners or entering new markets.